<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00682461</url>
  </required_header>
  <id_info>
    <org_study_id>S2110367</org_study_id>
    <nct_id>NCT00682461</nct_id>
  </id_info>
  <brief_title>Oral Tolerability Of Two Nicotine Dosage Forms</brief_title>
  <official_title>A Randomized, Open Label Study to Evaluate the Oral Tolerability of a Nicotine Prototype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the oral tolerability of a nicotine prototype
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 1</measure>
    <time_frame>From baseline to Week 1</time_frame>
    <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 6</measure>
    <time_frame>From baseline to Week 6</time_frame>
    <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 12</measure>
    <time_frame>From baseline to Week 12</time_frame>
    <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 14</measure>
    <time_frame>From baseline to Week 14</time_frame>
    <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>From baseline to Week 14</time_frame>
    <description>Adverse Event=any untoward medical occurrence in a subject following administration of an investigational product, which did not necessarily have a causal relationship with this treatment.
Serious Adverse Event=any untoward medical occurrence that at any dose; results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Healthy Volunteer Smokers</condition>
  <arm_group>
    <arm_group_label>Marketed formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Marketed nicotine replacement therapy product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prototype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nicotine prototype</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Marketed nicotine replacement therapy formulation</description>
    <arm_group_label>Marketed formulation</arm_group_label>
    <other_name>marketed NRT formulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Nicotine prototype</description>
    <arm_group_label>prototype</arm_group_label>
    <other_name>Nicotine prototype</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age:Males and females aged at least 18 years.

          -  Smoking status: a.Must have smoked 5 to 20 cigarettes per day for the previous 12
             months. b.Must be motivated to quit smoking upon randomization into study.

          -  Contraception:Females of childbearing potential who have been, in the opinion of the
             investigator, practicing a reliable method of contraception for at least two months
             prior to study participation and must agree to remain on an acceptable method of
             contraception while participating in the study period using the study medication.
             Acceptable methods of contraception are hormonal birth control, intrauterine device,
             double barrier methods, vasectomized partner or abstinence.

          -  Oral health:Must have good oral health (in the opinion of the Investigator) with no
             clinically significant oral pathology at screening.

          -  General health:Must have good general health (in the opinion of the Investigator) with
             no clinically significant and relevant abnormalities of medical history on physical
             examination at screening.

          -  Compliance:Understands and is willing, able and likely to comply with all study
             procedures and restrictions.

          -  Consent:Demonstrates understanding of the study and willingness to participate as
             evidenced by voluntary written informed consent and has received a signed and dated
             copy of the informed consent form.

        Exclusion Criteria:

          -  Pregnancy:Women who are known to be pregnant or who are intending to become pregnant
             over the duration of the study. Females of child-bearing potential will be required to
             undergo a urine pregnancy test which must be negative.

          -  Breast-feeding:Women who are breast-feeding.

          -  Nicotine use: a.Is unable/unwilling to stop using forms of tobacco. b.Is
             unable/unwilling to stop using other nicotine replacement therapy.

          -  Disease:Has a medical history, which in the opinion of the Investigator, would
             jeopardize the safety of the subject or impact the validity of the study results, e.g.
             known history of heart disease, recent myocardial infarction or cerebrovascular
             accident (i.e. within 12 weeks prior to the first study session), unstable angina,
             severe cardiac arrhythmia, diabetes or peptic ulcer.

          -  Oral condition: a.Has history of oral surgery (including extractions) within four
             weeks, operative dental work within seven days, or a presence of any clinically
             significant oral pathology (as determined by the Investigator) including lesions,
             sores or inflammation which would interfere with assessments. b.Has fixed retainers,
             orthodontic appliances, or either maxillary and/or mandibular dentures or other
             appliances which may interfere with the placement or wearing of the product. c.Has
             current or recurrent disease that could affect the site of application, the action,
             absorption or disposition of the study treatment, or clinical assessment. d.Has severe
             gingivitis, periodontitis or rampant caries, as diagnosed by the investigator. e.Has
             the presence of oral or peri-oral ulceration including herpetic lesions at the time of
             baseline (subjects with these lesions may be re-examined at a subsequent appointment
             and may be able to be admitted at a later date if the ulceration or herpetic lesion
             heals). f.Has elective dentistry scheduled during the study duration.

          -  Allergy/Intolerance: a.Has a known or suspected intolerance or hypersensitivity to the
             study materials (or closely related compounds) or any of their stated ingredients.
             b.Presence of a genetic deficiency with an inability to metabolize aspartame or
             phenylalanine or has been diagnosed with phenylketonuria.

          -  Clinical Study/Experimental medication: a.Participation in another clinical study or
             receipt of an investigational drug within 30 days of the screening visit at the start
             of the study. b.Previous participation in this study.

          -  Substance abuse: a) Current or recent (within two year of screening) alcohol or other
             substance abuse. b) Positive alcohol breath screen. c) Positive urine drug screen for
             cannabinoids, amphetamine, cocaine, ecstasy, methamphetamine or morphine.

          -  Urine glucose:Positive glucose urine screen.

          -  Personnel: a.Is an employee of the sponsor or the study site. b.Is a member of the
             same household as another subject in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2008</study_first_posted>
  <results_first_submitted>January 24, 2013</results_first_submitted>
  <results_first_submitted_qc>January 24, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 1, 2013</results_first_posted>
  <last_update_submitted>January 24, 2013</last_update_submitted>
  <last_update_submitted_qc>January 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine Tolerability NRT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at one clinical site in the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nicotine Mouth Strip (2.5 mg)</title>
          <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
        </group>
        <group group_id="P2">
          <title>Nicotine Lozenge (2.0 mg)</title>
          <description>Prticipants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nicotine Mouth Strip (2.5 mg)</title>
          <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
        </group>
        <group group_id="B2">
          <title>Nicotine Lozenge (2.0 mg)</title>
          <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.32" spread="11.79"/>
                    <measurement group_id="B2" value="42.84" spread="12.34"/>
                    <measurement group_id="B3" value="42.58" spread="12.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 1</title>
        <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
        <time_frame>From baseline to Week 1</time_frame>
        <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Mouth Strip (2.5 mg)</title>
            <description>Participants were instructed to take 2.5 mg Nicotine Mouth strip, not exceeding a maximum limit of 15 per day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Lozenge (2.0 mg)</title>
            <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 1</title>
          <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
          <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>Adverse Event=any untoward medical occurrence in a subject following administration of an investigational product, which did not necessarily have a causal relationship with this treatment.
Serious Adverse Event=any untoward medical occurrence that at any dose; results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect</description>
        <time_frame>From baseline to Week 14</time_frame>
        <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Mouth Strip (2.5 mg)</title>
            <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Lozenge (2.0 mg)</title>
            <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>Adverse Event=any untoward medical occurrence in a subject following administration of an investigational product, which did not necessarily have a causal relationship with this treatment.
Serious Adverse Event=any untoward medical occurrence that at any dose; results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect</description>
          <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Oral Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-oral Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 6</title>
        <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
        <time_frame>From baseline to Week 6</time_frame>
        <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Mouth Strip (2.5 mg)</title>
            <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Lozenge (2.0 mg)</title>
            <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 6</title>
          <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
          <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 12</title>
        <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
        <time_frame>From baseline to Week 12</time_frame>
        <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Mouth Strip (2.5 mg)</title>
            <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Lozenge (2.0 mg)</title>
            <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 12</title>
          <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
          <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 14</title>
        <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
        <time_frame>From baseline to Week 14</time_frame>
        <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Mouth Strip (2.5 mg)</title>
            <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
          </group>
          <group group_id="O2">
            <title>Nicotine Lozenge (2.0 mg)</title>
            <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum limit of 15 per day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Oral Soft Tissue Related Adverse Events at Week 14</title>
          <description>Oral Soft Tissue related adverse events= Any abnormality occuring in any of these: labial mucosa (including lips), gingival mucosa, buccal mucosa, mucogingival folds, hard and soft palates, tonsilar and pharyngeal areas, tongue, sublingual and submandibular areas, and salivary glands</description>
          <population>Analysis was based on safety population, which consisted of all randomized participants who took at least one dose of the study medication.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to Week 14</time_frame>
      <desc>All adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>Nicotine Mouth Strip (2.5 mg)</title>
          <description>Participants were instructed to take 2.5 mg Nicotine Mouth Strip, not exceeding a maximum limit of 15 per day</description>
        </group>
        <group group_id="E2">
          <title>Nicotine Lozenge (2.0 mg)</title>
          <description>Participants were instructed to take 2.0 mg Nicotine Lozenge, not exceeding a maximum of 15 per day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <description>Unrelated to the study treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral Mucosal Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gingival Ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Oral Discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Paraesthesia Oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Reflux Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastrooenteritis Viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="100"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mouth Injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Tooth Fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

